ARROWHEAD PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Contract Liability (Deferred Revenue) of $94.60 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Contract with Customer, Liability, Current $94.60M.
- 2026-03-31: Contract with Customer, Liability, Current $108.54M.
- 2025-12-31: Contract with Customer, Liability, Current $111.93M.
- 2025-09-30: Contract with Customer, Liability, Current $2.40M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $94.60M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $108.54M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $111.93M 10-Q · filed 2026-02-05 | |
| 2025-09-30 | $2.40M 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $22.98M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $43.27M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $0.00 10-Q · filed 2026-02-05 | |
| 2024-09-30 | $0.00 10-K · filed 2025-11-25 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $0.00 10-Q · filed 2024-02-06 | |
| 2023-09-30 | $866.00K 10-K · filed 2024-11-26 | |
| 2023-06-30 | $16.91M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $29.84M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $66.28M 10-Q · filed 2023-02-06 | |
| 2022-09-30 | $74.10M 10-K · filed 2023-11-29 | |
| 2022-06-30 | $84.29M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $97.87M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $108.65M 10-Q · filed 2022-02-02 | |
| 2021-09-30 | $111.06M 10-K · filed 2022-11-28 | |
| 2021-06-30 | $150.93M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $144.88M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $6.74M 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $19.29M 10-K · filed 2021-11-22 | $19.29M 10-K · filed 2020-11-23 |
| 2020-06-30 | $26.27M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $33.17M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $54.03M 10-Q · filed 2020-02-05 | |
| 2019-09-30 | $77.77M 10-K · filed 2020-11-23 | |
| 2019-06-30 | $75.68M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $90.89M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $124.93M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $600.00 10-K · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |